Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
作者:Michael M. Miller、Jacques Banville、Todd J. Friends、Mark Gagnon、Jon J. Hangeland、Jean-François Lavallée、Alain Martel、Harold O’Grady、Roger Rémillard、Edward Ruediger、François Tremblay、Shana L. Posy、Nick J. Allegretto、Victor R. Guarino、David G. Harden、Timothy W. Harper、Karen Hartl、Jonathan Josephs、Sarah Malmstrom、Carol Watson、Yanou Yang、Ge Zhang、Pancras Wong、Jing Yang、Michel Bouvier、Dietmar A. Seiffert、Ruth R. Wexler、R. Michael Lawrence、E. Scott Priestley、Anne Marinier
DOI:10.1021/acs.jmedchem.9b00186
日期:2019.8.22
monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure-activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation
为了确定新型抗血栓形成剂,我们通过在猴子血栓形成模型中开发和评估工具化合物UDM-001651,研究了蛋白酶激活的受体4(PAR4)拮抗作用。从高通量筛选开始,我们确定了基于咪唑并噻二唑的PAR4拮抗剂化学型。详细的结构-活性关系研究能够优化有效,选择性和口服生物利用的PAR4拮抗剂UDM-001651。UDM-001651在猴子血栓形成模型中进行了评估,显示具有强大的抗血栓形成功效,并且不会延长肾脏的出血时间。优异的疗效和安全性相结合,强有力地验证了PAR4拮抗作用是一种有前途的抗血栓形成机制。